🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Bio-tech startup Utopia Therapeutics raises $1.5 Mn led by Whale Tank

EntrackrEntrackr · 2m ago
Bio-tech startup Utopia Therapeutics raises $1.5 Mn led by Whale Tank
Medial

Utopia Therapeutics, a biotech company developing next-generation vaccines for chronic metabolic diseases, has secured $1.5 million in seed funding from Whale Tank. The proceeds will be utilized to accelerate the preclinical development of UT009, its lead immunotherapeutic candidate targeting obesity and support the advancement of UT009 toward regulatory toxicology studies, IND-enabling milestones, and Phase I human clinical trials, Utopia Therapeutics said in a press release. Co-founded in 2024 by Uday Saxena and Gopi Kadiyala, Utopia Therapeutics focuses on developing next-generation vaccines for chronic metabolic diseases, particularly obesity. The startup aims to deliver first-in-class vaccines for obesity and related metabolic diseases using novel scientific approaches. “Obesity is a global epidemic with limited long-term therapeutic options. UT009 represents a paradigm shift by differentiating it from current obesity drugs by addressing the root causes of weight gain. This investment enables us to move swiftly toward clinical translation,” said Uday Saxena and Gopi Kadiyala, co-founders of Utopia Therapeutics. According to the Hyderabad-based company, UT009 is a novel vaccine designed to reduce fat accumulation and improve metabolic health by targeting lipid-associated antigens. The company plans to scale up and commercialize Utopia’s UT018-based regenerative product line, built on GRAS-qualified, non-pharmaceutical applications.

1

Related News

Dronetech startup Zuppa raises $1.5 Mn in bridge round

EntrackrEntrackr · 1m ago
Dronetech startup Zuppa raises $1.5 Mn in bridge round
Medial

Dronetech startup Zuppa raises $1.5 Mn in bridge round Zuppa, a Chennai-based deep-tech startup focused on autonomous drone systems, has raised $1.5 million in a bridge funding round led by entrepreneur Rahul Dewan (founder of Srijan Technologies) with participation from Ajay Gupta (Capital Foods) and the Mangwani Family Office (ex-Aquapharm Chemicals). The round brings both capital and high-impact entrepreneurial backing to the company. The new funds will be used to strengthen Zuppa’s R&D and deepen its presence in defence and dual-use drone technologies. Founded by aerospace engineers, Zuppa builds fully indigenous drone intelligence platforms including flight control systems, vision guidance, secure cyber-physical stacks, and AI-based targeting. These systems are designed to operate independently of GPS and high-bandwidth internet, enabling performance in complex and remote environments. The firm claims to have built a high-barrier entry position in the defence drone segment and is already involved in post-Operation Sindoor deployments where Indian drone tech was found lacking. With deployments already underway and a patent-backed IP stack, Zuppa is also collaborating with academic institutions and government bodies to influence national drone policy and standards.

Avammune Therapeutics raises $12 Mn in Series A round

EntrackrEntrackr · 3m ago
Avammune Therapeutics raises $12 Mn in Series A round
Medial

Avammune Therapeutics and its subsidiary, Avammune Lifesciences, have secured $12 million in a Series A financing round co-led by Capital 2B, Shastra VC, and Kotak Lifesciences Fund I. The proceeds will be utilized to accelerate its proprietary pipeline, which targets the innate immune system, to develop orally bioavailable small molecules and support the clinical development of lead candidate AVA-NP-695 (an ENPP1 inhibitor). Co-founded in 2020 by Arun B. Papaiah, Srinivasan Namala, and Aditya Kulkarni, Avammune Therapeutics is a biopharmaceutical company discovering small molecule medicines that target the innate immune system for the treatment of cancer and autoimmune disorders. Its pipeline targets Osteosarcoma, Ewing’s Sarcoma, Triple-Negative Breast Cancer, GI cancers, and autoimmune disorders.

Bio-tech startup PeelON raises $1 Mn in seed round led by growX Ventures

EntrackrEntrackr · 9d ago
Bio-tech startup PeelON raises $1 Mn in seed round led by growX Ventures
Medial

Bio-tech startup PeelON raises $1 Mn in seed round led by growX Ventures PeelON, a bio-tech startup specialising in biodegradable, compostable packaging for fresh produce, has raised $1 million in a seed funding round led by deep-tech-focused VC firm growX Ventures along with participation from Boston Venture Group, Clean Energy Venture Group, and Climate Angels. The proceeds will be deployed to expand R&D and production facilities in Visakhapatnam, hire across sales (USA and India), R&D, and regulatory compliance, and launch marketing campaigns, PeelON said in a press release. Co-founded in 2020 by Taraka Ramji Moturu and Venkata Ravi Sankar Ummidi, PeelON develops plant-based films that extend the shelf life of fruits and vegetables by up to 3x. It operates on a B2B model, working with farmers, exporters, and retailers to eliminate single-use plastics at every stage of the fresh produce supply chain. According to PeelON, it offers two flagship products, engineered to address the respective pain points of bulk shipments and retail products. While its first product PeelON-Fresh offers liners for bulk shipments, its second product PeelON-Retail+ offers retail-ready bags with natural antimicrobial agents and ethylene scavengers to maintain freshness and reduce food spoilage. PeelON’s solutions are being commercially deployed across crops such as cilantro, broccoli, leafy greens, rambutan, and banana, with clients in Maharashtra and Andhra Pradesh in India, as well as in Texas, Florida, and California in the US. The company also has active collaborations with universities and compostable materials labs in the USA and India to expand its solutions to other items. The company plans to expand production capacity in India and the US, become the go-to packaging solution for sustainable exporters in India, Mexico, and Southeast Asia, and launch retail compostable packaging formats in the US and Canadian markets. It also aims to pilot a blockchain-enabled traceability platform for carbon and shelf-life validation.

Bio-tech startup Cellivate Technologies raises $1 Mn in seed round

EntrackrEntrackr · 1y ago
Bio-tech startup Cellivate Technologies raises $1 Mn in seed round
Medial

Bio-tech startup Cellivate Technologies has raised $1 million in a seed round led by Antler along with participation from Venture Catalysts, Hatcher+, and We Founder Circle. The funds will be used to accelerate its R&D efforts, scale up production of its innovative products, and expand its market reach, Cellivate said in a press release. Launched by Viknish Krishnan Kutty, Cellivate is developing innovative solutions to address critical challenges in cell culture and biomanufacturing. The company’s flagship products include advanced microcarriers for scaling up cell growth and a novel cell-based serum designed to replace fetal bovine serum. According to market research, the cell culture market, especially concerning microcarriers and serum, is expected to reach $33 billion by 2030. Cellivate says that its advanced microcarriers and cell-based serum alternatives have the potential to reduce costs, increase efficiency, and address ethical concerns in cell culture processes. Advancements in cell culture and biomanufacturing-related technologies will reduce society’s dependence on animal slaughter since several products/ingredients conventionally derived from animals can be procured from cells.

Avammune Therapeutics raises $12 Mn in Series A funding round

EntrackrEntrackr · 3m ago
Avammune Therapeutics raises $12 Mn in Series A funding round
Medial

Avammune Therapeutics and its subsidiary, Avammune Lifesciences, have secured $12 million (around Rs 100 crore) in a Series A financing round co-led by Capital 2B, Shastra VC, and Kotak Lifesciences Fund I, a fund managed by Kotak Alternate Asset Managers, with participation from IvyCap Ventures alongside existing investor 1Crowd. The proceeds will be utilized to accelerate its proprietary pipeline, which targets the innate immune system, to develop orally bioavailable small molecules and support the clinical development of lead candidate AVA-NP-695 (an ENPP1 inhibitor), Avammune Therapeutics said in a press release. Co-founded in 2020 by Arun B. Papaiah, Srinivasan Namala, and Aditya Kulkarni, Avammune Therapeutics is a biopharmaceutical company discovering small molecule medicines that target the innate immune system for the treatment of cancer and autoimmune disorders. Its pipeline targets Osteosarcoma, Ewing’s Sarcoma, Triple-Negative Breast Cancer, GI cancers, and autoimmune disorders. According to Avammune, its lead asset is an ENPP1 inhibitor that has demonstrated strong anti-tumor efficacy in several preclinical models of cancer and also in veterinary cancer patients in “compassionate use” settings. AVA-ADR is a potential first-in-class ADAR1 p150 inhibitor and one of the only ADAR1 inhibitors in the landscape to demonstrate in vivo efficacy. According to market research, the global immuno-oncology market is about $100 billion and is rapidly growing at a CAGR of 17%.

Download the medial app to read full posts, comements and news.